Access cutting-edge papillary kidney cancer treatment through this clinical trial at a research site in Little Rock. Study-provided care at no cost to qualified participants.
Access papillary kidney cancer specialists in Little Rock at no cost
This study follows strict safety protocols and ethical guidelines
All study-related papillary kidney cancer treatment provided free
This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread from where it first started (primary site) to other places in the body (metastatic). Papillary renal cell carcinoma (PRCC) is a type of kidney cancer that forms in the lining of the tiny tubes in the kidney that return filtered substances that the body needs back to the blood and remove extra fluid and
Sponsor: National Cancer Institute (NCI)
Check if you qualify for this papillary kidney cancer clinical trial in Little Rock, AR
If you're searching for papillary kidney cancer treatment options in Little Rock, AR, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Little Rock research site is actively enrolling participants for this clinical trial. You'll receive care from experienced papillary kidney cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.